title: Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties.
abstract: The development of 8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-ones 3 starting from (RS)-8-acenaphten-1-yl-1-phenyl-1,3, 8-triazaspiro[4.5]decan-4-one 1 is reported. The synthesis and the binding affinities at human OFQ and opioid (micro, kappa, delta) receptors of the stereoisomers 3a-f are described. In vitro the most selective compound, (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one 3c, was found to act as a full agonist at the OFQ receptor in the GTPgamma(35)S binding test. It turned out to be selective versus a variety of other neurotransmitter systems. When tested in vivo following intraperitoneal injection, compound 3c was found to decrease neophobia in a novel environment and to exhibit dose-dependent anxiolytic-like effects in the elevated plus-maze procedure, thus confirming the effects observed following intracerebroventricular infusion of the OFQ peptide in rat.
authors.affiliation: Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd., Grenzacherstr. 124, CH-4070, Basel, Switzerland. juergen.wichmann@roche.com
authors.forename: J
authors.initials: J
authors.lastname: Wichmann
authors.forename: G
authors.initials: G
authors.lastname: Adam
authors.forename: S
authors.initials: S
authors.lastname: Röver
authors.forename: M
authors.initials: M
authors.lastname: Hennig
authors.forename: M
authors.initials: M
authors.lastname: Scalone
authors.forename: A M
authors.initials: AM
authors.lastname: Cesura
authors.forename: F M
authors.initials: FM
authors.lastname: Dautzenberg
authors.forename: F
authors.initials: F
authors.lastname: Jenck
mesh_terms: D000525:Alprazolam / Q000494:pharmacology; D000818:Animals; D014151:Anti-Anxiety Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D001372:Aza Compounds / Q000138:chemical synthesis* / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D043803:Phenalenes; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid / Q000819:agonists* / Q000187:drug effects; D013141:Spiro Compounds / Q000138:chemical synthesis* / Q000494:pharmacology*; D000094942:Nociceptin Receptor
chemical_list: C415405:8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro(4.5)decan-4-one; D014151:Anti-Anxiety Agents; D001372:Aza Compounds; D043803:Phenalenes; D011957:Receptors, Opioid; D013141:Spiro Compounds; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D000525:Alprazolam; D000094942:Nociceptin Receptor